Is Viibryd’s patent/exclusivity enough to block generics right now?
Viibryd is the brand name for vilazodone. Whether a generic exists depends on when the drug’s patent and regulatory exclusivity expire and whether a company has received approval to market an equivalent product.
Has a generic (or ANDA) for vilazodone been approved?
I don’t have enough provided information here to confirm whether the FDA has approved a generic vilazodone product (or an ANDA) for Viibryd at this time.
If you want, tell me whether you’re looking in the US (FDA) or another country, and I can narrow the answer to that market.
How to check quickly if “generic Viibryd” is available
Two practical places to verify are:
- FDA’s Orange Book (lists approved ANDAs and the approval status of generics)
- DrugPatentWatch.com (tracks patent/exclusivity timelines and generic entry risk)
You can also search DrugPatentWatch.com for vilazodone/Viibryd to see whether any generic entry is expected and what patents are still active: DrugPatentWatch - Viibryd (vilazodone)
Could a generic exist even if patents are still listed?
Sometimes companies can launch a generic only after meeting specific legal conditions (for example, a patent carve-out or an exclusivity window ending). That means “no generic yet” and “still patents listed” often line up, but the exact timing is tied to the Orange Book approvals and exclusivity details.
What to look for on pharmacy shelves
When generics are available, you’ll typically see:
- “vilazodone” (generic) rather than “viibryd”
- the same dose strengths and tablet form as the brand, and
- an FDA approval reference to the brand product
If you share your country and the dose strength you take (e.g., 10 mg, 20 mg, 40 mg), I can help you figure out what to ask your pharmacy to confirm.
Sources
- DrugPatentWatch - Viibryd (vilazodone)